1 February 2021 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or the "Company")
Total Voting Rights
At 31 January 2021, the Company had 56,855,705 ordinary shares in issue, each carrying one voting right. This follows the issue of 9,000 new shares arising from the exercise of options by staff, such shares having been admitted under the Company's existing block listing arrangement.
As the Company holds no ordinary shares in treasury, the figure of 56,855,705 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
ENDS
ENQUIRIES:
| ReNeuron | +44 (0)20 3819 8400 |
| Olav Hellebø, Chief Executive Officer |
|
| Michael Hunt, Chief Financial Officer
|
|
| Buchanan (Media/Investor relations) | +44 (0) 20 7466 5000 |
| Mark Court, Sophie Wills, Tilly Abraham
|
|
| Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) | +44 (0) 20 7710 7600 |
| Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
|
|
| N+1 Singer (Joint Broker) | +44 (0) 20 7496 3000 |
| Aubrey Powell, James Moat, Tom Salvesen |
|
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
